Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Net Assets

Latest as of September 2025: CN¥8.93 Billion CNY ≈ $1.31 Billion USD

Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has net assets worth CN¥8.93 Billion CNY (≈ $1.31 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.98 Billion ≈ $1.61 Billion USD) and total liabilities (CN¥2.05 Billion ≈ $300.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Shenzhen Salubris Pharmaceuticals Co Ltd's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥8.93 Billion
% of Total Assets	81.31%
Annual Growth Rate	27.75%
5-Year Change	56.52%
10-Year Change	86.39%
Growth Volatility	116.17

Shenzhen Salubris Pharmaceuticals Co Ltd - Net Assets Trend (2006–2024)

This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Shenzhen Salubris Pharmaceuticals Co Ltd asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)

The table below shows the annual net assets of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024. For live valuation and market cap data, see Shenzhen Salubris Pharmaceuticals Co Ltd market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥8.75 Billion ≈ $1.28 Billion	+8.65%
2023-12-31	CN¥8.06 Billion ≈ $1.18 Billion	+0.99%
2022-12-31	CN¥7.98 Billion ≈ $1.17 Billion	-0.86%
2021-12-31	CN¥8.05 Billion ≈ $1.18 Billion	+43.89%
2020-12-31	CN¥5.59 Billion ≈ $818.24 Million	-16.12%
2019-12-31	CN¥6.67 Billion ≈ $975.50 Million	-2.98%
2018-12-31	CN¥6.87 Billion ≈ $1.01 Billion	+11.57%
2017-12-31	CN¥6.16 Billion ≈ $901.18 Million	+12.79%
2016-12-31	CN¥5.46 Billion ≈ $798.98 Million	+16.28%
2015-12-31	CN¥4.70 Billion ≈ $687.12 Million	+23.96%
2014-12-31	CN¥3.79 Billion ≈ $554.32 Million	+20.84%
2013-12-31	CN¥3.13 Billion ≈ $458.73 Million	+20.26%
2012-12-31	CN¥2.61 Billion ≈ $381.44 Million	+22.11%
2011-12-31	CN¥2.13 Billion ≈ $312.36 Million	+14.43%
2010-12-31	CN¥1.87 Billion ≈ $272.96 Million	+14.91%
2009-12-31	CN¥1.62 Billion ≈ $237.55 Million	+517.49%
2008-12-31	CN¥262.90 Million ≈ $38.47 Million	+80.12%
2007-12-31	CN¥145.96 Million ≈ $21.36 Million	+37.08%
2006-12-31	CN¥106.48 Million ≈ $15.58 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shenzhen Salubris Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 16451.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥5.09 Billion	58.46%
Common Stock	CN¥1.11 Billion	12.80%
Other Comprehensive Income	CN¥668.96 Million	7.68%
Other Components	CN¥1.84 Billion	21.06%
Total Equity	CN¥8.71 Billion	100.00%

Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Market Cap

The table below lists competitors of Shenzhen Salubris Pharmaceuticals Co Ltd ranked by their market capitalization.

Company	Market Cap
CTP N.V. AS:CTPNV	$8.37 Billion
PT Pantai Indah Kapuk Dua Tbk JK:PANI	$8.37 Billion
Hyundai Autoever Corp KO:307950	$8.37 Billion
Builders FirstSource Inc NYSE:BLDR	$8.37 Billion
Hotai Motor Co Ltd TW:2207	$8.36 Billion
Blueprint Medicines Corp NASDAQ:BPMC	$8.36 Billion
Merlin Properties SOCIMI SA LS:MRL	$8.35 Billion
National Retail Properties Inc NYSE:NNN	$8.35 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shenzhen Salubris Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 8,018,993,837 to 8,712,145,683, a change of 693,151,846 (8.6%).
Net income of 601,569,148 contributed positively to equity growth.
Dividend payments of 546,035,242 reduced retained earnings.
Other comprehensive income increased equity by 34,226,092.
Other factors increased equity by 603,391,848.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥601.57 Million	+6.9%
Dividends Paid	CN¥546.04 Million	-6.27%
Other Comprehensive Income	CN¥34.23 Million	+0.39%
Other Changes	CN¥603.39 Million	+6.93%
Total Change	CN¥-	8.64%

Book Value vs Market Value Analysis

This analysis compares Shenzhen Salubris Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 6.56x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 316.67x to 6.56x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥0.16	CN¥51.29	x
2007-12-31	CN¥0.19	CN¥51.29	x
2008-12-31	CN¥0.34	CN¥51.29	x
2009-12-31	CN¥1.91	CN¥51.29	x
2010-12-31	CN¥1.78	CN¥51.29	x
2011-12-31	CN¥2.04	CN¥51.29	x
2012-12-31	CN¥2.49	CN¥51.29	x
2013-12-31	CN¥2.99	CN¥51.29	x
2014-12-31	CN¥3.63	CN¥51.29	x
2015-12-31	CN¥4.39	CN¥51.29	x
2016-12-31	CN¥5.11	CN¥51.29	x
2017-12-31	CN¥5.79	CN¥51.29	x
2018-12-31	CN¥6.35	CN¥51.29	x
2019-12-31	CN¥6.22	CN¥51.29	x
2020-12-31	CN¥5.36	CN¥51.29	x
2021-12-31	CN¥7.53	CN¥51.29	x
2022-12-31	CN¥7.23	CN¥51.29	x
2023-12-31	CN¥7.19	CN¥51.29	x
2024-12-31	CN¥7.82	CN¥51.29	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shenzhen Salubris Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.90%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 14.99%
• Asset Turnover: 0.38x
• Equity Multiplier: 1.20x
Recent ROE (6.90%) is below the historical average (20.90%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	32.16%	16.85%	1.28x	1.49x	CN¥23.59 Million
2007	50.11%	20.93%	1.37x	1.75x	CN¥58.54 Million
2008	44.48%	22.18%	1.29x	1.55x	CN¥90.65 Million
2009	13.31%	25.39%	0.48x	1.09x	CN¥53.60 Million
2010	19.07%	27.38%	0.60x	1.17x	CN¥168.99 Million
2011	19.01%	27.48%	0.60x	1.15x	CN¥192.02 Million
2012	24.39%	34.73%	0.61x	1.14x	CN¥374.77 Million
2013	26.54%	35.68%	0.64x	1.16x	CN¥517.48 Million
2014	27.58%	36.16%	0.62x	1.22x	CN¥664.34 Million
2015	27.58%	36.40%	0.65x	1.17x	CN¥806.97 Million
2016	26.05%	36.43%	0.59x	1.22x	CN¥860.38 Million
2017	23.99%	34.95%	0.61x	1.13x	CN¥846.59 Million
2018	21.89%	31.35%	0.59x	1.19x	CN¥792.13 Million
2019	11.02%	16.00%	0.58x	1.19x	CN¥66.26 Million
2020	1.10%	2.22%	0.40x	1.26x	CN¥-489.97 Million
2021	6.64%	17.45%	0.33x	1.15x	CN¥-269.65 Million
2022	8.02%	18.30%	0.36x	1.23x	CN¥-156.98 Million
2023	7.23%	17.24%	0.36x	1.17x	CN¥-221.83 Million
2024	6.90%	14.99%	0.38x	1.20x	CN¥-269.65 Million

Industry Comparison

This section compares Shenzhen Salubris Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,784,080,233
Average return on equity (ROE) among peers: 10.27%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shenzhen Salubris Pharmaceuticals Co Ltd (002294)	CN¥8.93 Billion	32.16%	0.23x	$8.37 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$52.15 Million	21.80%	0.58x	$1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$24.03 Million	18.61%	1.45x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.05 Billion	10.46%	0.19x	$5.18 Billion
Livzon Pharmaceutical Group Inc (000513)	$3.01 Billion	11.93%	0.53x	$2.81 Billion
Wedge Industrial Co Ltd (000534)	$654.70 Million	1.92%	0.87x	$2.95 Billion
Yunnan Baiyao Group Co Ltd (000538)	$19.92 Billion	17.54%	0.52x	$13.85 Billion
Hainan Haiyao Co Ltd (000566)	$1.33 Billion	7.89%	0.52x	$949.23 Million
Tus Pharmaceutical Group Co Ltd (000590)	$268.54 Million	1.60%	1.47x	$391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$870.26 Million	1.00%	1.90x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$10.66 Billion	9.94%	0.14x	$3.30 Billion

About Shenzhen Salubris Pharmaceuticals Co Ltd

SHE:002294 China Drug Manufacturers - Specialty & Generic

Market Cap

$8.37 Billion

CN¥57.18 Billion CNY

Market Cap Rank

#2542 Global

#322 in China

Share Price

CN¥51.29

Change (1 day)

-1.18%

52-Week Range

CN¥38.05 - CN¥68.30

All Time High

CN¥68.30